利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.023 秒)

    Hydrodynamically balancing oral drug delivery system with biphasic release
    5.
    发明申请
    Hydrodynamically balancing oral drug delivery system with biphasic release 审中-公开
    流体动力平衡口服药物输送系统与双相释放

    公开(公告)号：US20060099245A1

    公开(公告)日：2006-05-11

    申请号：US10514674

    申请日：2002-05-21

    申请人： Manoj Kumar ,  Naresh Talwar ,  Rajeev Raghuvanshi ,  Ashok Rampal

    发明人： Manoj Kumar ,  Naresh Talwar ,  Rajeev Raghuvanshi ,  Ashok Rampal

    IPC分类号： A61K9/48 ,  A61K9/64 ,  A61K9/22 ,  A61K31/403

    CPC分类号： A61K9/0065 ,  A61K9/2866 ,  A61K9/4891

    摘要： The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. The pharmaceutical composi-tion, either in the form of pellets (multiparticulate or single unit dosage form), beads, granules, capsules or tablets, is retained in the stomach while selectively delivering the drug(s) at gastrointestinal levels and upper parts of the small intestine over an extended period of time. The release of the drug from the said pharmaceutical composition is characterized by a biphasic release profile of the drug substance, which exhibits both immediate and controlled release characteristics.

    摘要翻译： 本发明涉及具有双相释放特征的口服药物递送系统，其包含多孔基质，其包含至少一种药物物质，糖，缓释聚合物，气体产生组分和任选的药物可接受的辅助成分，其中 药物组合物还包含所述药物的涂层。 以颗粒形式（多颗粒或单一单位剂型），珠粒，颗粒，胶囊或片剂的药物组合物保留在胃中，同时选择性地将药物在胃肠水平和 小肠在较长时间内。 药物从所述药物组合物的释放的特征在于药物物质的双相释放曲线，其表现出立即和控制释放特征。

    Bupropion hydrochloride solid dosage forms
    6.
    发明申请
    Bupropion hydrochloride solid dosage forms 审中-公开
    盐酸安非他酮固体剂型

    公开(公告)号：US20060020040A1

    公开(公告)日：2006-01-26

    申请号：US10534910

    申请日：2003-11-17

    申请人： Manish Chawla ,  Rajeev Raghuvanshi ,  Ashok Rampal

    发明人： Manish Chawla ,  Rajeev Raghuvanshi ,  Ashok Rampal

    IPC分类号： A61K31/138

    CPC分类号： A61K31/135 ,  A61K9/2013 ,  A61K9/2054

    摘要： The present invention relates to solid dosage forms that contain bupropion hydrochloride and glucono delta lactone or its corresponding open chain hydroxy acid derivative. The bupropion hydrochloride retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40° C. and 75% relative humidity. The solid dosage form may be in the form of a tablet, a capsule, or a granulate with or without an immediate release profile, a modified release profile, or an extended release profile.

    摘要翻译： 本发明涉及含有安非他酮盐酸盐和葡萄糖酸-δ内酯或其相应的开链羟基酸衍生物的固体剂型。 盐酸安非他酮在40℃和75％相对湿度下保存3个月后，保持盐酸安非他酮的至少80％的效力。 固体剂型可以是片剂，胶囊或具有或不具有立即释放特征，改变释放特征或延长释放特征的颗粒形式。

    Modified release, multiple unit drug delivery systems
    7.
    发明申请
    Modified release, multiple unit drug delivery systems 审中-公开
    改良释放，多单位药物输送系统

    公开(公告)号：US20060257482A1

    公开(公告)日：2006-11-16

    申请号：US10517101

    申请日：2003-06-09

    申请人： Patrik Kumar ,  Girish Jain ,  Ashok Rampal ,  Ravikumar Nithyanandam ,  Rajeev Raghuvanshi

    发明人： Patrik Kumar ,  Girish Jain ,  Ashok Rampal ,  Ravikumar Nithyanandam ,  Rajeev Raghuvanshi

    IPC分类号： A61K31/553 ,  A61K31/554 ,  A61K31/522 ,  A61K31/496 ,  A61K31/366 ,  A61K31/22 ,  A61K31/137 ,  A61K9/26

    CPC分类号： A61K9/5078 ,  A61K9/209 ,  A61K9/5031 ,  A61K31/137 ,  A61K31/64

    摘要： The invention relates to novel modified release multiple unit systems, and methods of preparing these systems, which can be easily compressed into tablets or filled into capsules or sachets without affecting the desired release characteristics of the pharmaceutical active ingredients incorporated within the systems. The multiple unit tablet includes multiple units. Each unit includes at least one core having an outer surface, a first coating layer surrounding at least a portion of the outer surface of the core and having an outer surface, one or more rate controlling polymers, and one or more one active pharmaceutical ingredients. The coating layer includes one or both of the one or more active pharmaceutical ingredients and the one or more rate controlling polymers. The tablet may further include an outer layer on the outer surface of the unit which includes a material that is one or both of elastic and compressible. The material may be a wax materials, such as polyethylene glycol's (PEGS).

    摘要翻译： 本发明涉及新型改性释放多单位体系，以及制备这些系统的方法，其可以容易地压制成片剂或填充到胶囊或小药囊中，而不影响并入系统内的药物活性成分的所需释放特征。 多单元平板电脑包括多个单元。 每个单元包括至少一个具有外表面的芯，围绕芯的外表面的至少一部分并具有外表面，一个或多个速率控制聚合物和一种或多种活性药物成分的第一涂层。 涂层包括一种或多种活性药物成分和一种或多种速率控制聚合物中的一种或两种。 片剂还可以包括在单元的外表面上的外层，其包括弹性和可压缩之一或两者的材料。 该材料可以是蜡材料，例如聚乙二醇（PEGS）。

    Clarithromycin formulations having improved bioavailability
    10.
    发明申请
    Clarithromycin formulations having improved bioavailability 审中-公开
    克拉霉素制剂具有改善的生物利用度

    公开(公告)号：US20050163857A1

    公开(公告)日：2005-07-28

    申请号：US10509704

    申请日：2003-04-03

    申请人： Ashok Rampal ,  Rajeev Raghuvanshi ,  Manoj Paruthi

    发明人： Ashok Rampal ,  Rajeev Raghuvanshi ,  Manoj Paruthi

    IPC分类号： A61K9/14 ,  A61K9/20 ,  A61K31/7048 ,  A61K31/7052

    CPC分类号： A61K31/7048 ,  A61K9/146 ,  A61K9/2077

    摘要： A pharmaceutical composition includes micronized clarithromycin and exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmicronized clarithromycin. The clarithromycin may have a particle size less than approximately 35 microns. One process for preparing an extended release tablet of the clarithromycin includes micronizing the clarithromycin; blending the micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients; granulating the blend; and compressing to form a tablet. To treat a bacterial infection in a mammal in need of treatment, a patient may be administered a pharmaceutical composition that includes micronized clarithromycin.

    摘要翻译： 药物组合物包括微粉碎的克拉霉素并且相对于包含非微量克拉霉素的药物组合物显示出改善的溶出特性。 克拉霉素可以具有小于约35微米的粒度。 制备克拉霉素缓释片剂的一个方法包括使克拉霉素微粉化; 将微粉碎的克拉霉素与一种或多种速率控制聚合物和药学上可接受的赋形剂混合; 造粒混合物; 并压缩形成片剂。 为了治疗需要治疗的哺乳动物的细菌感染，可以给予患者包括微粉碎的克拉霉素的药物组合物。